Who makes Oxymetazoline HCl 0.025%?

Oxymetazoline HCl 0.025% is developed by Eye Therapies, LLC.

What development phase is Oxymetazoline HCl 0.025% in?

Oxymetazoline HCl 0.025% is in Phase 2.

Last reviewed 2026-05-15 · How we verify

Oxymetazoline HCl 0.025%

Eye Therapies, LLC · Phase 2 active Small molecule

At a glance

Generic name	Oxymetazoline HCl 0.025%
Sponsor	Eye Therapies, LLC
Modality	Small molecule
Phase	Phase 2

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Norepinephrine for Hypotension in Cesarean Section (NA)
A Single-Center, Randomized, Double-Masked, Placebo and Active Controlled, Dose-Ranging Evaluation of the Duration of Action of Brimonidine Tartrate Ophthalmic Solution in the Control of Ocular Redness Induced by Conjunctival Allergen Challenge (CAC) (PHASE2)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Oxymetazoline HCl 0.025% CI brief — competitive landscape report
Oxymetazoline HCl 0.025% updates RSS · CI watch RSS
Eye Therapies, LLC portfolio CI